Meeting
2017 ASCO Annual Meeting
Design of ALTA-1L (ALK in lung cancer trial of brigatinib in first-line), a randomized phase 3 trial of brigatinib (BRG) versus crizotinib (CRZ) in tyrosine kinase inhibitor (TKI)-naive patients (pts) with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).
Authors
Marcello Tiseo
University Hospital of Parma, Parma, Italy
Marcello Tiseo , Sanjay Popat , Scott N. Gettinger , Solange Peters , Jeff Haney , David Kerstein , D. Ross Camidge
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02737501
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS9098)
DOI
10.1200/JCO.2017.35.15_suppl.TPS9098
Abstract #
TPS9098
Poster Bd #
423a
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Health-related quality of life (HRQoL) results from ALTA-1L: Phase 3 study of brigatinib vs crizotinib as first-line (1L) ALK therapy in advanced ALK+ non-small cell lung cancer (NSCLC).
First Author: Rosario Garcia Campelo
Poster
2023 ASCO Annual Meeting
Integrated efficacy and safety of brigatinib in patients with ALK TKI-naive advanced ALK+ NSCLC in the ALTA-1L and J-ALTA studies.
First Author: D. Ross Camidge
Poster
2023 ASCO Annual Meeting
Management of patients with ALK-positive advanced non-small cell lung cancer who received brain radiotherapy on study in the phase 3 CROWN trial.
First Author: Todd Michael Bauer
Poster
2022 ASCO Annual Meeting
Progression-free survival with subsequent anticancer therapies from a phase 3 trial of lorlatinib in treatment-naive patients (pts) with ALK+ advanced non–small cell lung cancer (NSCLC).
First Author: Benjamin J. Solomon